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Background
Asthma is a chronic inflammatory disease induced by
Type 2helper T cells (Th2) and eosinophils. Vascular
cell adhesion molecule-1(VCAM-1) is the regulatory
receptor implicated with recruiting eosinophils andlym-
phocytes to pathologic site in asthma. A monoclonal
antibody (mAb)against VCAM-1 may attenuate allergic
inflammation and pathophysiologicfeatures of asthma.
Weevaluated whether a recently developed human anti-
VCAM-1mAb can inhibit pathophysiologic features of
asthma in a murine asthma modelinduced by ovalbumin
(OVA).
Methods
We evaluated whether human anti-VCAM-1 mAb binds
to human ormouse VCAM-1. Leukocyte adhesion inhibi-
tion assay was performed toevaluate the in vitro blocking
activity of human anti-VCAM-1 mAb. OVAsensitized
BALB/c mice were treated with human anti-VCAM-1
mAb orisotype control Ab before intranasal OVA chal-
lenge. We evaluated airwayhyperresponsiveness (AHR)
and cell counts in bronchoalveolar lavage (BAL)fluid, mea-
sured inflammatory cytokines, and examined histopatholo-
gicalfeatures, including VCAM-1 immunohistochemistry.
Results
The human anti-VCAM-1 mAb bound to human and
mouse VCAM-1molecules and inhibited adhesion of
human leukocytes in vitro. AHR andinflammatory cell
counts in BAL fluid were reduced in mice treated
withhuman anti-VCAM-1 mAb as compared to a con-
trol Ab. The levels ofinterleukin (IL)-5 and IL-13, and
transforming growth factor-b in lung tissuewere decreased
in treated mice. Human anti-VCAM-1 mAb reduced gob-
let cellhyperplasia and peribronchial fibrosis. In vivo
VCAM-1 expression decreasedin treated group.
Results
Human anti-VCAM-1 mAb can attenuate allergic inflam-
mationand pathophysiological features of asthma in OVA
induced murine asthmamodel. This data suggested that
human anti-VCAM-1 mAb could be an additionalanti-
asthma therapeutic medicine.
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